Global
Global Home
|
CSL Behring US
|
CSL Plasma
|
All CSL Behring Web Sites
All Sites
Choose country
Argentina
Australia
Austria
Belgium/Luxembourg
Brazil
Canada
China
Czech Republic
Denmark
France
Germany
Greece
Italy
Japan
Mexico
Netherlands
Nordic
Spain
Switzerland
UK
USA
CSL Plasma US
CSL Plasma Germany
Home
About CSL Behring
Products
Patient Commitment
Environment, Health, Safety & Sustainability
Quality & Safety
CSL Research & Development
Clinical Trials
Other Areas of Business
Partners
News Room
Careers
Contact Us
Home
> Home
Product Overview
CSL Behring develops, manufactures and markets protein based therapies, including:
Bleeding Disorders Therapies
Fluid Replacement Therapies
Hereditary Angioedema (HAE) Therapies
Immunoglobulin Therapies
Pulmonary Therapies
Wound Healing Therapies
Global Product Portfolio
Features
New on BioBlog
Yesli Paillacán faced many challenges growing up with a primary immunodeficiency in Chile
Paul Perreault on Being Passionate and Direct
Read his remarks in the Australian Financial Review about managing CSL into the future.
Personal Stories
BU Hockey Coach Inspires Kids with Hemophilia B
News
30-June-2017
FDA Approves HAEGARDA for the Prevention of HAE Attacks
19-May-2017
Innovative Treatment for Hemophilia Earns CSL Behring NORD 2017 ...
19-April-2017
Therapeutic Goods Administration Approves AFSTYLA
®
10-April-2017
Improving Access to Lifesaving Bleeding Disorders Treatments
05-April-2017
CSL Behring Supports Alpha-1 Global Research Conference & ...
View all news
Share
More Options
